Trials / Completed
CompletedNCT01786811
Serious Illness Communication Project
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 994 (actual)
- Sponsor
- Dana-Farber Cancer Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to evaluate the impact of implementing a "Serious Illness Conversation Guide" to guide patient/family-clinician discussions and planning about end-of-life care decisions. The goal of the intervention is to improve achievement of patient care priorities and peacefulness at the end of life for patients with serious and life-threatening illness and their families. We hypothesize that patients whose physician is trained to use and adheres to the elements of the Serious Illness Conversation Guide will demonstrate enhanced consistency between documented key priorities and care received, and will experience greater peace in the final month of life; similarly, their families will experience higher satisfaction with care.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Training | 1. Initial Training: The training program for clinicians randomized into the intervention arm will be 2.5 hours. The project will be introduced and the Serious Illness Conversation Guide shared. The training session will include a brief didactic session on "Challenges in discussing advance care planning/values and goals" followed by practice using the SICG. 2. Coaching and Feedback: We will also provide individual coaching for clinicians. Clinicians will be able to contact the study doctor to request coaching/debriefing on a challenging case; one of the investigators will respond within 24-48 hours for urgent or distressing cases (up to 72 hours on weekends). In-the-moment coaching will be by telephone or in person. |
Timeline
- Start date
- 2012-06-01
- Primary completion
- 2016-06-01
- Completion
- 2016-06-01
- First posted
- 2013-02-08
- Last updated
- 2019-01-22
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01786811. Inclusion in this directory is not an endorsement.